Levonorgestrel And Ethinyl Estradiol Tablet
Product Images NDC 68462-637

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Levonorgestrel And Ethinyl Estradiol (NDC 68462-637). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig-1 (Fig 1)

Two pharmacokinetic line graphs displaying plasma concentrations of Levonorgestrel and Ethinyl Estradiol over time in hours. The top graph shows Levonorgestrel plasma concentration (ng/mL) on Days 1, 14, and 28, while the bottom graph depicts Ethinyl Estradiol plasma concentration (pg/mL) for the same time points. Both include error bars representing standard deviation.*

FDA Label Image

Fig-2 (Fig 2)

A bar chart depicting the cumulative percentage of subjects experiencing amenorrhea across 13 sequential pill packs of Levonorgestrel and Ethinyl Estradiol tablets. The x-axis represents the pill pack number from 1 to 13, while the y-axis shows the percentage of subjects, increasing from 0% to 100%. The graph shows an increasing trend in amenorrhea percentage with each successive pill pack from about 0% at pack 1 to nearly 60% at pack 13.*

FDA Label Image

Fig-3 (Fig 3)

A bar chart comparing four groups: ever-users non-smokers, controls non-smokers, ever-users smokers, and controls smokers across four age ranges (15-24, 25-34, 35-44, 45 and older). The y-axis represents a numeric value up to 250. Values increase markedly for the 45 and older category, especially for ever-users smokers, and moderately for ever-users non-smokers in the same age group. The chart is adapted from a 1981 publication by P.M. Layde and V. Beral in Lancet.*

FDA Label Image

Fig-4 (Fig 4)

A bar chart displaying the percentage of subjects experiencing bleeding or spotting only across multiple pill packs of Levonorgestrel and Ethinyl Estradiol tablets. The x-axis lists pill pack numbers, and the y-axis shows the percentage of subjects from 0 to 100%. Bleeding requires sanitary protection, while spotting does not. The chart illustrates a general decline in overall bleeding and spotting percentages over consecutive pill packs.*

FDA Label Image

Fig-5 (Fig 5)

A bar chart depicting the percentage of subjects with adverse events lasting 4 or more days and 7 or more days, distributed across different pill packs labeled from -2 to -13. The y-axis shows the percentage of subjects from 0 to 100. The number of subjects for each pill pack is shown below the x-axis. The chart compares the duration of symptoms among subjects over multiple pill packs in a study setting.*

FDA Label Image

Gkenmark Logo

FDA Label Image

Levonorgestrel Structure And Ethinyl Estradiol Structure (Image 01)

Chemical structure diagrams of the active ingredients Levonorgestrel and Ethinyl Estradiol with molecular formulas C21H28O2 and C20H24O2, respectively. Molecular weights are 312.45 g/mol for Levonorgestrel and 296.40 g/mol for Ethinyl Estradiol.*

FDA Label Image

Glenmark Logo (Image 02)

FDA Label Image

Image 04

Packaging label for Levonorgestrel and Ethinyl Estradiol Tablets, USP 0.09 mg/0.02 mg oral tablets by Glenmark Pharmaceuticals Inc., USA. The carton states it contains 3 blisters, each with 28 tablets. The label includes dosing information, storage instructions, and manufacturer details, featuring a green and beige floral design with the Glenmark logo.*

FDA Label Image

Image 05

A forest plot titled 'Risk of Breast Cancer with Combined Oral Contraceptive Use' showing effect estimates (odds ratio/relative risk) from multiple studies. The plot lists studies by name and year on the left, with corresponding effect estimates and confidence intervals depicted as points and horizontal lines across a scale ranging approximately from -1.5 to 2, centered on 1, indicating relative risk values for breast cancer associated with contraceptive use.*

FDA Label Image

Precentage Of Subjects Reporting Bleeding Or Spotting (Image 08)

A bar chart displaying the percentage of subjects experiencing bleeding and spotting only across different pill packs for Levonorgestrel and Ethinyl Estradiol tablets. The x-axis represents pill pack numbers from -2 to -13, and the y-axis shows the percentage of subjects up to 100%. Bleeding is indicated by solid bars, while spotting only is shown by hatched bars. The chart includes notes on subject numbers with 20 days of data and sanitary protection requirements.*

FDA Label Image

Precentage Of Subjects Reporting Greater Than Or Equal (Image 09)

A bar chart depicting the percentage of subjects with 4 or more days and 7 or more days of an unspecified measure across different pill packs numbered from -2 to -13. The x-axis represents the pill pack numbers, and the y-axis shows the percentage of subjects ranging from 0 to 90%. A legend distinguishes between 4 or more days (black bars) and 7 or more days (white bars). The sample size (N) for each pill pack is listed below the x-axis.*

FDA Label Image

Img-1 (Img 1)

An instructional diagram showing a hand removing a tablet from a blister pack of Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.09 mg/0.02 mg strength. The blister pack is organized in a grid format with four rows labeled as weeks 1 through 4 and columns labeled by days of the week (Tuesday through Sunday). The image includes a note about keeping the package out of reach of children.*

FDA Label Image

Img-2 (Img 2)

An instructional illustration of a Levonorgestrel and Ethinyl Estradiol oral tablet blister pack with 28 tablet slots arranged in a 4-week calendar format. The pack is labeled with strengths of 0.09 mg and 0.02 mg and shows a hand peeling back the tablet cover for Saturday in week 1. Days of the week are marked above each column, and weeks 1 to 4 are numbered along the side, illustrating tablet usage schedule.*

FDA Label Image

Laminate

Label for Levonorgestrel and Ethinyl Estradiol Tablets, USP 0.09 mg/0.02 mg by Glenmark Pharmaceuticals Inc. The label shows a blister pack containing 28 oral tablets, with dosage and storage information. Manufactured by Glenmark Pharmaceuticals Limited, India, and labeled for Glenmark Pharmaceuticals Inc., USA. The label includes warnings about child safety and product handling instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.